Data on VIVUS' Qnexa To Be Presented at the National Medical Association Annual Assembly
MOUNTAIN VIEW, Calif., July 29 /PRNewswire-FirstCall/ -- VIVUS,
Inc. (NASDAQ:VVUS)
today announced that data on Qnexa®, an investigational drug
candidate, will be presented at the 2010 National Medical
Association Annual Convention & Scientific Assembly (NMA),
being held from July 31 - August 4, 2010 in Orlando, Florida. Dr.
A. Julian Munoz, from The Division of Metabolism, Endocrinology
& Diabetes at the University of Michigan, will deliver an oral
presentation on Saturday, July 31st entitled: "Weight Loss With
Low-Dose, Controlled-Release Phentermine/Topiramate in African
American Subjects vs. Non-African American Subjects: Pooled 1-Year
Data from Two Phase 3 Trials." The data will also be presented in a
poster presentation session on Tuesday, August 3rd.
Following are details about the upcoming presentation:
2010 National Medical Association Annual Convention &
Scientific Assembly (NMA) in Orlando, Florida
Date and Time: Saturday, July 31, 2010, 8:00-2:00 PM (actual
time to be decided morning of - sorry)
Location: Gaylord Palms Hotel, Orlando, Florida Session: Oral Presentation Session
Presentation Title: Weight Loss With Low-Dose,
Controlled-Release Phentermine/Topiramate in African American
Subjects vs Non-African American Subjects: Pooled 1-Year Data from
Two Phase 3 Trials.
Chairs: Henry R. Black, MD and George L. Bakris, MD Presenter: A. Julian Munoz, MD, MSPH About VIVUS
VIVUS is a biopharmaceutical company developing innovative,
next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health. The company's lead product in
clinical development, Qnexa®, has completed phase 3 clinical
trials for the treatment of obesity and an NDA has been filed and
accepted by the FDA, with an action date of October 28, 2010. Qnexa
is also in phase 2 clinical development for the treatment of type 2
diabetes and obstructive sleep apnea. In the area of sexual health,
VIVUS is in phase 3 development with avanafil, a potentially
best-in-class PDE5 inhibitor for the treatment of erectile
dysfunction. MUSE® (alprostadil), a first generation therapy
for the treatment of ED, is already on the market and generating
revenue for VIVUS. For more information about the company, please
visit www.vivus.com.
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking
statements are based on VIVUS' current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; uncertainties of patent
protection and litigation; uncertainties of government or third
party payer reimbursement; reliance on sole source suppliers;
limited sales and marketing efforts and dependence upon third
parties; risks related to the development of innovative products;
and risks related to failure to obtain FDA clearances or approvals
and noncompliance with FDA regulations. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval and commercialization of new products. There
are no guarantees that future clinical studies discussed in this
press release will be completed or successful or that any product
will receive regulatory approval for any indication or prove to be
commercially successful. VIVUS does not undertake an obligation to
update or revise any forward-looking statement. Investors should
read the risk factors set forth in VIVUS' Form 10-K for the year
ended December 31, 2009 and periodic reports filed with the
Securities and Exchange Commission.
CONTACT:
--------
VIVUS, Inc. Investor Relations: The Trout Group
Timothy E. Morris Brian Korb
Chief Financial Officer 646-378-2923
650-934-5200
Pure Communications,
Media Relations: Inc.
Dan Budwick
973-271-6085
Source: VIVUS, Inc.
CONTACT: VIVUS, Inc., Timothy E. Morris, Chief Financial
Officer,
+1-650-934-5200; Investor Relations: The Trout Group, Brian
Korb,
+1-646-378-2923; or Media Relations: Pure Communications, Inc., Dan
Budwick,
+1-973-271-6085
Web Site: http://www.vivus.com/
Posted: July 2010
